Latest Ai Driven Drug Discovery News

Page 1 of 2
Algorae Pharmaceuticals has unveiled breakthrough synergy predictions from its AI platform AlgoraeOS v2, spotlighting 90 high-potential CBD-drug combinations and surpassing models from Google DeepMind.
Victor Sage
Victor Sage
12 Dec 2025
Algorae Pharmaceuticals has secured a $384,466 cash refund from the Australian Taxation Office, reinforcing its financial position to advance AI-driven drug discovery programs.
Ada Torres
Ada Torres
10 Dec 2025
Algorae Pharmaceuticals has independently validated its AI-driven drug combination platform, AlgoraeOS v1, confirming its ability to predict synergistic cancer drug pairs. The company has also launched an upgraded version, AlgoraeOS v2, poised to enhance drug discovery efforts.
Ada Torres
Ada Torres
5 Dec 2025
Algorae Pharmaceuticals has launched a Loyalty Options Offer, allowing eligible shareholders to purchase options at a nominal price, aiming to reward loyalty and support future growth funding.
Ada Torres
Ada Torres
17 Nov 2025
Starpharma’s 2025 AGM highlighted breakthrough partnerships and clinical progress, positioning the biotech for growth. Key deals with Genentech and Radiopharm Theranostics underpin a promising pipeline and expanding revenue streams.
Ada Torres
Ada Torres
14 Nov 2025
Algorae Pharmaceuticals has launched AlgoraeOS Version 2, a major AI platform upgrade that surpasses leading models including those from Google DeepMind, promising to accelerate drug-combination discovery.
Ada Torres
Ada Torres
10 Nov 2025
Pathkey.AI reports strong validation of its TrialKey AI platform’s predictive accuracy and announces key leadership changes as it advances toward commercial scale.
Ada Torres
Ada Torres
31 Oct 2025
Algorae Pharmaceuticals has broadened its commercial footprint in Australia and New Zealand through key licensing agreements, while advancing its AI-driven drug discovery platform and strengthening leadership.
Victor Sage
Victor Sage
28 Oct 2025
Pathkey.AI has upgraded its TrialKey platform to include drug-level molecular and pharmacokinetic features, enhancing clinical trial predictions and opening doors to AI-driven drug discovery.
Ada Torres
Ada Torres
18 Sept 2025
Algorae Pharmaceuticals has advanced its AI-driven drug discovery platform into preclinical validation through a strategic collaboration with the Peter MacCallum Cancer Centre, while progressing its therapeutic pipeline and commercial leadership.
Ada Torres
Ada Torres
29 July 2025
Opyl Limited unveils a bold strategic pivot to enhance its AI-driven drug discovery platform, leveraging a vast proprietary dataset and leadership upgrades to redefine clinical trial innovation.
Ada Torres
Ada Torres
10 June 2025
Algorae Pharmaceuticals has secured a significant A$318,771 R&D tax incentive rebate from the Australian Taxation Office, providing a non-dilutive cash injection to advance its AI-driven drug discovery programs.
Ada Torres
Ada Torres
6 June 2025